Brief: Phio Pharmaceuticals Announces Positive Recommendation From Safety Monitoring Committee Of Phase 1B Clinical Study Of Phio S Lead Compound Ph-762
28/05/2024 22:05
Phio Pharmaceuticals Corp PHIO.O :
* PHIO PHARMACEUTICALS ANNOUNCES POSITIVE RECOMMENDATION
FROM
SAFETY MONITORING COMMITTEE OF PHASE 1B CLINICAL STUDY OF PHIO S
LEAD COMPOUND PH-762
Source text for Eikon: ID:n0001683168-24-003849
Further company coverage: PHIO.O
Recent news on Phio Pharmaceuticals
See all newsPhio Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Phio Pharmaceuticals Corp - Enters At The Market Offering Agreement With H.C. Wainwright On April 8, 2026
Brief: Phio Pharmaceuticals Corp Announces Key Tumor Response Data From PH-762 Trial
Brief: Phio Pharmaceuticals Corp To Begin Toxicology Study For Ph-762 Before Human Trials - SEC Filing
Brief: Phio Pharmaceuticals Corp Files For Offering Of Up To 11.8 Million Common Shares By The Selling Stockholders - SEC Filing